TX-COGNITIVE-SPACE
Cognitive Space today announced it has been selected to participate in the Amazon Web Services (AWS) Space Accelerator , a business support program for startups seeking to use AWS to help solve the biggest challenges in the space industry. This opportunity will support Cognitive Space efforts to revolutionize satellite operations by bringing the power of artificial intelligence and machine learning to mission operations and collection planning. Cognitive Space provides New Space organizations with sophisticated tools for optimizing revenue and performance yield as their satellite constellations grow and scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005120/en/
New for 2021, the four-week AWS Space Accelerator curriculum provides hands-on AWS Cloud and technical training, mentorship, coaching, and business support in collaboration with Seraphim, one of the world’s leading investment groups focused exclusively on the space industry, who will provide business development and investment guidance.
Cognitive Space will rely on AWS Cloud infrastructure for its own Space-focused software products - including licensed services, underlying platform architecture, development & test environments, and AI/ML training and processing workloads. Cognitive Space will take advantage of AWS services for scalability, cost-effectiveness, security, reliability, and global reach.
“Being one of the few startups accepted into the AWS Space Accelerator is a great honor and we appreciate the confidence AWS has placed in us,” said Scott Herman, CEO of Cognitive Space. “We’re very excited about the mentoring opportunity that the accelerator provides to startups like ours, and we look forward to working closely with AWS and Seraphim as we build our company.” Guy de Carufel, CTO of Cognitive Space, added “We depend on Amazon Web Services to provide high-reliability and scalable infrastructure for the satellite operations services we deliver to our customers and partners, and we are eager to learn more from the AWS experts during the accelerator.”
As one of 10 companies chosen for this opportunity out of a field of approximately 200 startups, Cognitive Space will receive up to $100,000 in AWS Activate credit, AWS Cloud training and support, mentorship, and additional business development resources including opportunities to speak with space-savvy venture investors.
“AWS looks forward to collaborating with our finalists to advance their inspiring vision for transforming how we understand, operate in, and benefit from space,” said Clint Crosier, director of the Aerospace and Satellite business at AWS. “Congratulations to our finalists, who were selected from hundreds of impressive startups from across the global space industry. The cloud is uniquely suited to spur the success of space companies in so many ways, and we are excited to help these companies achieve their biggest goals.”
Proposals were judged on several factors including the innovative and unique nature of the project, the overall value the solution will bring to the space industry, the creative application of AWS to solve problems, and the team’s ability to deliver on its specific mission.
For more information on the AWS Space Accelerator, visit https://seraphim.vc/aws/accelerator/ .
About Cognitive Space
Cognitive Space is developing advanced automation systems for the space industry with a particular focus on the software management of satellite constellations, including mission management, collection planning, communication link management, and modeling & simulation of future capabilities.
Our early focus is on orchestrated collection management for the explosion of new remote sensing constellations - multi-phenomenology, large-fleet constellations of small satellite sensors that offer unprecedented facility monitoring, activity monitoring, and pattern-of-life analysis for national security and commercial organizations with a global monitoring mission.
Cognitive Space is developing an AI-driven solution for near real-time dynamic mission planning for Low Earth Orbit (LEO) Satellites. By 2030, research analysts predict 15-20x growth in deployed satellites in service, from 3000 in 2021 to ~50,000 satellites in orbit. Satellite constellations are increasingly being tasked by government and commercial consumers for use cases including communications, agriculture, environmental protection, meteorology, navigation, national defense, and myriad other commercial, military and governmental use cases.
The Cognitive Space satellite constellation management platform allows operators to reduce command and control lead time, reduce human errors and streamline satellite asset integration. For commercial operators this allows them to maximize service capacity, increase revenue and margin, and optimize performance yield. Cognitive Space’s platform is multi-purpose, serving the needs of the Federal Government, US Department of Defense and commercial enterprises.
More information about Cognitive Space can be found at http://www.cognitivespace.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005120/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom